Ascend Wellness Holdings (AAWH) Non-Current Deferred Tax Liability (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Non-Current Deferred Tax Liability of $20.2 million for Q1 2026, down 14.17% year-over-year from $23.5 million in Q1 2025, and down 6.15% quarter-over-quarter from $21.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $20.2 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 14.17% year-over-year to $20.2 million; the TTM figure through Mar 2026 stood at $20.2 million (down 14.17% YoY), while the FY2025 annual figure was $21.5 million, down 8.21% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $20.2 million, down from $21.5 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $110.6 million in Q4 2023, with the low at $276000.0 in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $25.6 million (2024), against an average of $30.8 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability surged 11292.03% in 2023, then slumped 78.81% in 2024.
- Ascend Wellness Holdings' Non-Current Deferred Tax Liability stood at $33.6 million in 2022, then soared by 229.18% to $110.6 million in 2023, then plunged by 78.81% to $23.4 million in 2024, then decreased by 8.21% to $21.5 million in 2025, then decreased by 6.15% to $20.2 million in 2026.
- Business Quant data shows AAWH's Non-Current Deferred Tax Liability at $20.2 million in Q1 2026, $21.5 million in Q4 2025, and $18.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Ascend Wellness Holdings | 97.42 Mn | 30.42 Mn | 45.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.79 Mn |
| Jun 30, 2026 | 17.79 Mn |
| Mar 31, 2026 | 20.19 Mn |
| Mar 31, 2026 | 20.19 Mn |
| Dec 31, 2025 | 21.52 Mn |
| Dec 31, 2025 | 21.52 Mn |
| Sep 30, 2025 | 18.74 Mn |
| Sep 30, 2025 | 18.74 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 23.53 Mn |
| Mar 31, 2025 | 23.53 Mn |
| Dec 31, 2024 | 23.44 Mn |
| Dec 31, 2024 | 23.44 Mn |
| Sep 30, 2024 | 25.57 Mn |
| Sep 30, 2024 | 25.57 Mn |
| Jun 30, 2024 | 30.27 Mn |
| Jun 30, 2024 | 30.27 Mn |
| Mar 31, 2024 | 32.48 Mn |
| Mar 31, 2024 | 32.48 Mn |